

IN THE UNITED STANDERS TENT AND TRADEMARK OFFICE

In re application of:

ANDERSEN et al.

Atty. Dck. No. 108281-00000-

Application No.: 09/581,511

Examiner: D. Lukton

Filed: October 6, 2000

Art Unit: 1653

For: HEMIASTERLIN ANALOGS

EXTRA CLAIMS FEE TRANSMITTAL

Commissioner for Patents Washington, D.C. 20231

September 26, 2002

Sir:

Attached is an Amendment in the above-identified application.

A statement to establish small entity status under 37 C.F.R. §§1.9 and 1.27 is attached. ☐ Small entity status of this application under 37 C.F.R. §§1.9 and 1.27 has been established by a statement previously submitted.

The filing fee has been calculated as shown below.

	(Column 1)	(Column 2)	(Column 3)	
**************************************	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	
TOTAL CLAIMS	53 MINUS	21	= 32	
INDEP CLAIMS	1 MINUS	3	= 0	
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL	ENTITY
-------	---------------

SMALL ENTITY				
RATE	ADD'L FEE	ΩR		
x 9	\$			
x 42	\$			
+140	\$	ΩR		
	\$			

OTHER THAN A

SMALL ENTITY			
OR.	RATE	ADD'L FEE	
	x 18	\$ 576	
	x 84	\$	
OR	+280	\$	
		\$ 576	

The Commissioner is hereby authorized to charge the fee of \$576.00 and any other fees that may be required to complete this filing, or to credit any overpayment, to Deposit Account No. 01-2300 referencing docket number 108281-00000.

Respectfully submitted,

D. Daniel Dzara, II

Registration No. 47,543

Customer No. 004372 ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W., Suite 400

Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RECEIVED

OCT 0 2 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ANDERSEN et al

Application Number: 09/581,51%

Filed: October 6, 2000

For: HEMIASTERLIN ANALOGS

Art Unit: 1653

Examiner: D. Lukton

Atty. Docket No. 108281-00000

RESPONSE

Commissioner of Patent Washington, D.C. 20231

September 26, 2002

Sir:

Further to the Office Action dated March 27, 2002, a Petition for Extension of Time for Three Months being attached hereto, the following is a full and complete response.

IN THE CLAIMS:

Please cancel Claims 1-21 and enter new Claims 22-74:

(New) A compound or pharmaceutically acceptable salt thereof, having the formula:

D1 FC:103 576.00 CH

wherein:

R₁ and R₂ are independently selected from the group consisting of H, R, and ArR-,

RECEIVED

OCT 0 2 2002

TECH CENTER 1600/2900